Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment

•Old drug for new application: trichosanthin can serve as a cancer vaccine adjuvant for effectively stimulating anti-tumor immunity.•The liposomal novel nanovaccine is characterized by an ‘all-in-one’ recombinant form of antigen and adjuvant.•The vaccination is targeting TAMs and the selective elimination of TAMs can activate anticancer immunity and thus remodel TIME.•The efficacy of this vaccine is demonstrated in various tumor models, indicating its application universality.